Thursday, May 28, 2015

Using Radiolabeled CTMs in Early Phase Development



While the requirements for using traditional “cold” clinical trial materials are well understood, radiolabeled drugs come with a few special regulatory and development hoops. For starters, attaching the radioactive isotope to your CTM sometimes involves developing a new synthetic pathway, a process that requires CMC expertise and a deep understanding of organic chemistry. Once synthesized, radiolabeled drugs often exhibit different stability and impurity profiles which must be understood to ensure these changes don’t impact the validity of the study. These and other issues present special challenges related to CGMP compliance and patient safety during the clinical trial.
 
ABC Laboratories will expand on this important topic at the 12th International Symposium on the Synthesis and Application of Isotopically Labelled Compounds on the campus of Princeton University June 7-11. Join Wayland Rushing, Ph.D., ABC Senior Scientific Advisor at # AM/PM June 11 for a podium presentation titled, “CGMP Radiosynthesis for Early Clinical Trials: A Unique Challenge.”

Thursday, May 21, 2015

ABC Wins Industry Awards 3 Years in a Row


Columbia, Missouri - 05/07/15 ABC Laboratories, Inc. has been named a 2-category winner in the 2015 CRO Leadership Awards presented by Life Science Leader magazine. Based on an annual survey of over 2,300 industry executives, this year's awards recognize service providers who were rated by industry as being in the top 10% of CROs. ABC received awards in Innovation and Regulatory categories.

"ABC is honored to have been recognized by industry three years in a row. It is rewarding to see investments aimed at delivering "better insight" and "better outcomes" to our clients are earning our organization a reputation for excellence," said John Bucksath, ABC's President and CEO.

Life Science Leader developed the annual CRO Leadership Awards in 2012 to honor top performers based on leading industry research conducted by professional market research agency Nice Insight. For this year's program, Life Science Leader narrowed the field of award winners by selecting only those companies that placed in the top 10% of each category, rather than the top 20% as was used in previous years.

In the May 2015 issue of Life Science Leader, the magazine asserted importance of this program. "Unlike other industry awards which are given based on a voting or nomination process, the only votes that count towards the CRO Leadership Awards are those of the pharmaceutical and biopharmaceutical companies using CRO services."

About ABC Laboratories

ABC Laboratories provides IND-enabling, registration and post-commercialization analytical support for the development, quality control and lifecycle management of innovative therapies and generic medicines. The company's personalized, results-based approach to development strategy is backed by decades of experience delivering GLP and CGMP-compliant analytical testing services across all types of active pharmaceutical ingredients and formulations. Through development know-how, cross-disciplinary technical expertise, and applied experience with evolving global regulatory frameworks, ABC helps efficiently manage programs for large and small molecule drugs, medical devices and combination products.

For additional information, contact Kristein King at 573-777-6209.

Information about the CRO Leadership Awards can be found at www.croleadreshipawards.com

Tuesday, May 19, 2015

New Frontiers in the Analysis of GMO Crop Proteins


By Glenn Petrie, Ph.D.
Senior Scientific Advisor
ABC Laboratories
www.abclabs.com


Genetically Modified Organisms (GMO) have been on the market for over two decades. These plants have been engineered for a variety of properties including:

  • Herbicide resistance
  • Cold/heat tolerance
  • Disease resistance
  • Increased yield
  • Improved quality
  • Pest resistance

Either internally or through licensing agreements large Agro Science companies have combined many of these properties into a single species. This may result in the introduction of 10-20 modified proteins. Each protein is present at different levels in each plant tissue and these levels typically change within the lifespan of the crop. The public concern with GMO crops has led to stringent control. The licensing requirements require careful control of the plants (particularly seeds), multiple field trials and careful monitoring of the modified plant proteins.

This presents quite an analytical challenge: 10-20 modified proteins in up to 12 different plant tissues. Sample preparation alone presents a daunting task. Plants are separated into their component tissues and each tissue macerated (multi-step), often lyophilized and ground to a fine homogeneous powder. The proteins are extracted, typically requiring different extraction methods depending upon the particular protein or tissue.

Once prepared and extracted actual quantitation of the proteins is required. The technique must be sensitive (low ng/mL), specific (thousands of proteins) and precise (crops are sampled several times during their lifecycle). Based on these requirements the methods available are:

  • ELISA
  • Western
  • LC/MS/MS

ELISAs are currently the method of choice. As I discussed in a previous blog (“WES, an alternative to ELISA”, 4/15/15), ELISAs possess the sensitivity and specificity required for GMOs, but not the day-to-day precision and are labor intensive. Automated Western analysis, as performed with the Wes™ system (Protein Simple®), alleviates many of the issues of with ELISA. It shows excellent day-to-day precision and is highly automated. However, both of these methods have relatively low sample throughput, 25-35 samples per plate with total analysis time from 2.5 – 18 hours. Given the hundreds of samples generated for a single GMO field trial, each of which require analysis of 10-20 different proteins, these techniques require man-months of analysis time. While ELISA can be multiplexed, this too is a laborious process and is better suited for analysis of a single matrix (plasma).

Within the last few years the use of proteomics, specifically LC/MRM/MS, has appeared in the literature for the analysis of GMO proteins. This technique appears to possess all the requirements necessary including high throughput. To provide the specificity required the mass/charge ratio must be determined for each of the proteins of interest. Typically the necessary sensitivity cannot be obtained analyzing intact proteins; therefore, proteolytic peptides are utilized. The entire plant extract is proteolytically digested (e.g. trypsin, Lys-C, etc.). This mixture of thousands of peptides is then analyzed by UPLC/MS/MS. Most of the peptides co-elute with multiple other peptides, but through the use of powerful proteomic software the peptides of interest can be teased out of the background. The chromatographic resolution is then optimized and the use of MRM (Multi Reaction Monitoring) is incorporated. In MRM, the peptide ion is separated by its mass/charge ratio in Q1, reacted in Q2 to produce daughter ions fragments which are further separated in Q3. MRM increases the sensitivity of the method 100-fold and provides an additional level of specificity by monitoring two daughter ions. Optimal precision is obtained through use of internal standards, usually synthetic 13C-labeled daughter ions. While this analysis requires substantial development time (as does ELISA), once developed it is a highly automated (walk-away). Its ultimate advantage is that MS/MRM can be multiplexed; there are reports of twelve or more proteins quantitated in a single analysis. This results in sample throughput 5-10 fold greater than ELISA or Western.

In summary, MRM/MS has the following advantages:

  • Accurate
  • Highly specific – two daughter ions
  • No requirement for antibodies
  • High throughput/multiplexing
  • Highly automated

While currently not the method of choice, MRM/MS seems poised to make enormous inroads for the analysis of protein levels in GMO plants.